key: cord-0838909-dty86tyd
authors: Schweizer, Tiziano A.; Shambat, Srikanth Mairpady; Vulin, Clément; Hoeller, Sylvia; Acevedo, Claudio; Huemer, Markus; Gomez-Mejia, Alejandro; Chang, Chun-Chi; Baum, Jeruscha; Hertegonne, Sanne; Hitz, Eva; Hofmaenner, Daniel A.; Buehler, Philipp K.; Moch, Holger; Schuepbach, Reto A.; Brugger, Silvio D.; Zinkernagel, Annelies S.
title: Blunted Fas signaling favors RIPK1-driven neutrophil necroptosis in critically ill COVID-19 patients
date: 2021-03-19
journal: bioRxiv
DOI: 10.1101/2021.03.19.436166
sha: 6082b61c9c509c14651826b2bca5344aaefcf939
doc_id: 838909
cord_uid: dty86tyd

Critically ill COVID-19 patients are characterized by a severely dysregulated cytokine profile and elevated neutrophil counts, which are thought to contribute to disease severity. However, to date it remains unclear how neutrophils contribute to pathophysiology during COVID-19. Here, we assessed the impact of the dysregulated cytokine profile on the tightly regulated cell death program of neutrophils. We show that in a subpopulation of neutrophils, canonical apoptosis was skewed towards rapidly occurring necroptosis. This phenotype was characterized by abrogated caspase-8 activity and increased RIPK1 levels, favoring execution of necroptosis via the RIPK1-RIPK3-MLKL axis, as further confirmed in COVID-19 biopsies. Moreover, reduction of sFas-L levels in COVID-19 patients and hence decreased signaling to Fas directly increased RIPK1 levels and correlated with disease severity. Our results suggest an important role for Fas signaling in the regulation of cell death program ambiguity via the ripoptosome in neutrophils during COVID-19 and a potential therapeutic target to curb inflammation and thus influence disease severity and outcome.

To investigate the fate of neutrophil cell death during COVID-19, we looked at critically ill patients 115 enrolled in our prospective intensive care unit (ICU) cohort (Table S1 ). Neutrophils were isolated 116 within the first four days upon ICU admission (acute phase). In parallel, neutrophils from healthy 117 donors were isolated. Neutrophils were stimulated with auto-or heterologous plasma and assessed 118 for short term viability using flow cytometry ( Fig. 1A and B, S1A) . Stimulation with acute phase 119 COVID-19 plasma decreased the proportion of live cells and increased the proportion of RCD, as 120 indicated by Annexin V positive staining, of both COVID-19 and healthy donor neutrophils. (Fig. 1B   121 and C). Furthermore, pre-stimulation with COVID-19 plasma and subsequent bacterial challenge 122 underscored the cell-death prone phenotype of both COVID-19 and healthy donor neutrophils in the 123 COVID-19 environment, simulated by addition of COVID-19 plasma (Fig. S1B) . In contrast, 124 neutrophils from the same COVID-19 patients during recovery phase (discharged from ICU or SARS-125 CoV-2 negative in a non-critical state), or healthy donor neutrophils stimulated with recovery phase 126 plasma, displayed no difference in proportion of viable and dying cells, as compared to stimulation 127 with healthy plasma (Fig. 1D) , highlighting a transient effect of acute phase COVID-19 plasma on 128 RCD induction in neutrophils. 129 To characterize the type of RCD the neutrophils succumbed to, we employed time lapse microscopy, 130 using the cell-permeable DNA-dye Hoechst and the cell-impermeable DNA-dye SYTOX TM green. 131 This approach revealed that COVID-19 plasma stimulation induced lytic RCD, linked to expulsion of 132 DNA around the lysed cells, but distinct from classical NETs formation, while less cell lysis was 133 observed upon stimulation with healthy plasma (Fig. 1E , S1, C and D, Video 1 and 2). This was in 134 accordance with findings by Middleton (Fig. S1E) . Tamoxifen has been shown to augment the innate immune function of 144 neutrophils as well as increase NETs formation (Corriden et al., 2015) . In line with these previous 145 findings, classical NETs (Fig. S1F) and apoptotic bodies were observed (Fig. S1, G and H) . We 146 analyzed cell death kinetics as proportion of SYTOX+ cells over time ( Fig. 1F and S2 , A, B and C) 147 and verified that COVID-19 neutrophils died at a higher rate when stimulated with auto-as compared 148 to heterologous plasma, resulting in a significantly increased proportion of dead cells (Fig. 1, F Since neutrophils usually die via caspase mediated apoptosis, we assessed whether caspases might 153 be involved in the observed lytic RCD. Interestingly, caspase inhibition showed no effect on short 154 term survival of neutrophils stimulated with COVID-19 plasma, confirming that neutrophils underwent 155 caspase independent lytic RCD (Fig. 2, A, B and S2D) . However, caspase blockage did not show 156 any effect on short term survival upon healthy plasma stimulation, potentially due to the fact that 157 caspases are usually only activated later on during the lifespan of neutrophils (Schwartz et al., 2012) . 158 Therefore, we also assessed long term survival in the COVID-19 and healthy plasma environment. 159 Here, we found that COVID-19 plasma had rather the opposite outcome on long term as compared 160 to short term stimulation, with higher proportions of neutrophils surviving as compared to healthy might also apply to SARS-CoV-2. 168 A caspase-impaired environment might favor the occurrence of necroptosis over apoptosis. 169 Necroptosis is described to differ from apoptotic cell death by release of damage associated 170 molecular patterns (DAMPs) known to trigger inflammation and decreased release of classical 171 cytokines, such as members of the TNF superfamily for neutrophils (Kearney and Martin, 2017) . 172 Therefore, we assessed the secretion of selected DAMPs and cytokines. COVID-19 plasma 173 stimulation resulted in significantly higher lactate dehydrogenase (LDH), DNA, S100A8/A9 and 174 calreticulin (CALR) release as well as slightly elevated MPO as compared to healthy plasma 175 stimulation (Fig. 2, E and F) . DAMPs, especially S100A8/A9, have previously been described to be difference, minimizing their potential pivotal role (Fig. S3C) . 233 Two other well-known death receptor pathways are Fas/Fas-L and TRAIL-R1/TRAIL. We found 234 significantly lower sFas-L concentrations in plasma from COVID-19 patients as compared to healthy 235 donors, which was in line with a recent study (Abers et al., 2021) , and equal levels of TRAIL (Fig.   236 3A). Importantly, during the recovery phase of these patients, the concentration of sFas-L was 237 significantly higher as compared to their acute phase, reaching levels of healthy donors (Fig. S3D) . 238 Assessing the corresponding receptors, Fas and TRAIL-R1, we observed significantly higher Fas 239 expression on neutrophils derived from COVID-19 patients as compared to healthy donors, whereas 240 TRAIL-R1 expression displayed no difference (Fig. 3B) . It has only recently been described that concentrations of sFas-L when stimulated with auto-as compared to heterologous plasma (Fig. 3C) . 249 Flow cytometry analysis revealed that neutrophils stimulated with COVID-19 plasma produced 250 significantly lower levels of Fas-L (Fig. 3D) 254 We reasoned that sFas-L might be beneficial for survival of COVID-19 neutrophils. Indeed, addition 255 of recombinant human sFas-L to COVID-19 neutrophils significantly increased the proportion of live 256 cells and decreased RCD induction in the COVID-19 environment (Fig. 3, E and F) . Blocking sFas-257 L from binding to Fas by employing a Fas-blocking antibody on the other hand increased the rate of 258 RCD significantly, also during healthy plasma stimulation, confirming that binding of sFas-L to Fas 259 is required for enhanced survival of COVID-19 neutrophils (Fig. 3, G and H) . Next, we assessed 260 whether sFas-L stimulation influenced RIPK1 levels and caspase-8 activity. Indeed, we found that 261 treatment with sFas-L decreased RIPK1 levels significantly during COVID-19, but not healthy, 262 plasma stimulation (Fig. 3I) . This occurred independently of caspase-8 (Fig. 3J) and caspase-3/7 263 activity (Fig. 3K) , suggesting that sFas-L acted as a pro-survival signal in the COVID-19 264 environment. (Fig. 4B) , as well as IL-6 ( Fig. 4C) , but not CRP (Fig. 4D) in the USZ SOC group. These bilirubin levels (Fig. 4E) and low platelet counts (Fig. 4F) , further highlighting the devastating effect 285 of neutrophil necroptosis on coagulation and tissue damage, as has been shown to impact COVID-286 19 severity (Liu et al., 2020; Radermecker et al., 2020). In line with these findings, low sFas-L levels 287 were linked to increased LOV (Fig. 4G) and also LOS (Fig. 4H) in the USZ SOC group. We observed 288 no correlation of sFas-L to disease severity in the RECOVERY SOC, even though sFas-L levels 289 were similar in RECOVERY as well as USZ SOC group (Fig. S3M) . Synthetic glucocorticoids, such Fig. 1C) , the later showed enhanced 295 viability (Fig. S3N) . However, prescription of synthetic glucocorticoids during viral pneumonia is still Table S1 . 

An immune-based biomarker signature is associated with mortality 462 in COVID-19 patients

Lymphopenia-induced T cell proliferation 466 is a hallmark of severe COVID-19. bioRxiv

Antibody-induced procoagulant platelets in severe 470 COVID-19 infection

The Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in 474

Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis

Increased CD95 (Fas) and PD-1 479 expression in peripheral blood T lymphocytes in COVID-19 patients

Neutrophils sense microbe size and selectively release 483 neutrophil extracellular traps in response to large pathogens

Bacterial pulmonary superinfections 488 are associated with unfavourable outcomes in critically ill COVID-19 patients

Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell 494 ratio as an early marker for severe COVID-19

Cutting Edge: Blockade of Inhibitor of

Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and 571

Granulocyte-Macrophage Colony-Stimulating Factor Delays 576

Neutrophil Constitutive Apoptosis Through Phosphoinositide 3-Kinase and Extracellular 577 Signal-Regulated Kinase Pathways

Neutrophil extracellular traps in ischemic 581 stroke thrombi

How Neutrophils Meet Their End

Differential Signalling and Kinetics of Neutrophil Extracellular Trap Release 586 Revealed by Quantitative Live Imaging

Bilirubin Levels as Potential Indicators of Disease Severity in 590

Coronavirus Disease Patients: A Retrospective Cohort Study

Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in 594 systemic lupus erythematosus-prone B6.Sle1.Yaa animals

Neutrophil 599 and monocyte dysfunctional effector response towards bacterial challenge in critically

Intranasal immunization with killed unencapsulated whole cells 603 prevents colonization and invasive disease by capsulated pneumococci

Neutrophil 609 extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory 610 distress syndrome

Viral infection and the evolution of caspase 612 8-regulated apoptotic and necrotic death pathways

Endothelial dysfunction and thrombosis in patients with COVID-19 -Brief report

Activated platelets induce MLKL-driven neutrophil necroptosis and 620 release of neutrophil extracellular traps in venous thrombosis

Excessive neutrophils and neutrophil extracellular traps 624 contribute to acute lung injury of influenza pneumonitis

Neutrophils and COVID-19: Nots, NETs, and knots

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit 632 than MLKL deficiency in mouse models of inflammation and tissue injury

The regulation of FasL expression during activation-induced 635 cell death (AICD)

637 and A. Oberst. 2014. RIPK1 both positively and negatively regulates RIPK3 638 oligomerization and necroptosis

SARS-CoV-2 649 triggered neutrophil extracellular traps (NETs) mediate COVID-19 pathology

Granulocyte colony-stimulating factor delays neutrophil apoptosis by inhibition of calpains 656 upstream of caspase-3

Neutrophil extracellular traps 659 infiltrate the lung airway, interstitial and vascular compartments in severe Covid-19

Inflammasomes are activated in response to 669

SARS-CoV-2 infection and are associated with COVID-19 severity in patients

How glucocorticoids 672 affect the neutrophil life

Characterization of the ripoptosome and its 674 components: Implications for anti-inflammatory and cancer therapy

NIH Image to ImageJ : 25 years of 677 image analysis

Severe COVID-19 Is Marked 693 by a Dysregulated Myeloid Cell Compartment

Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19

Constitutive Apoptosis and Prolong Human Neutrophil Lifespan

Neutrophils 705 induce apoptosis of lung epithelial cells via release of soluble Fas ligand

Membrane Fas ligand kills 708 human peripheral blood T lymphocytes, and soluble fas ligand blocks the killing

Caspase-8-Dependent Inflammatory Responses Are Controlled by Its 713

Endothelial cell infection 716 and endotheliitis in COVID-19

Triggered by Ligation of Adhesion Molecules following GM-CSF Priming

Necroptosis and neutrophil-Associated disorders 722 review-Article

Prognostic factors associated with 725 mortality risk and disease progression in 639 critically ill patients with COVID-19 in 726

Europe: Initial report of the international RISC-19-ICU prospective observational cohort

Mechanical Ventilation in COVID-19: Interpreting the Current Epidemiology

Corticosteroid administration for viral 731 pneumonia: COVID-19 and beyond

Infection-induced NETosis is a dynamic process 736 involving neutrophil multitasking in vivo

Inhibiting PSMα-induced neutrophil necroptosis protects mice with MRSA pneumonia by 739 blocking the agr system

High Level of Neutrophil Extracellular 742

Traps Correlates with Poor Prognosis of Severe Influenza A Infection

Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct 749

Immune Response Landscapes of COVID-19 and Influenza Patients

Experimental overview. (B and C) Representative flow cytometry plots of acute COVID-762 19 (n=10) and healthy donor (n=10) neutrophils stimulated with auto-or heterologous plasma 763 for 4 h (B) and quantification of live (Annexin V-/7AAD-), dying (Annexin V+/7AAD-) and dead 764 (Annexin V+/7AAD+) neutrophils (C). (D) Quantification of live

COVID-19 (n=7) or healthy donor (n=6) neutrophils stimulated with auto-or heterologous 766 plasma for 4 h. (E) Representative time lapse microscopy of acute COVID-19 neutrophils 767 stimulated with auto-or heterologous plasma for 3 h. Cells were stained with Hoechst 33342 768 (blue) and SYTOX TM green. Images were taken every ten minutes. Scale bar, 30 μm. Arrows 769 indicate cells with membrane breakdown

Left: COVID-19 neutrophils, right: healthy neutrophils. (G and H) Quantification of 772 cell death rate (G) and (H) proportion at 3 h of COVID-19 (n=10) or healthy neutrophils (n=5) 773 stimulated with auto-or heterologous plasma. See also Videos 1 and 2. Connected squares 774 represent one donor

P values are indicated within the graphs. FOV, field of view

A-D) Representative flow cytometry plots at 4 h (A) or 18 h post stimulation (C) and 789 quantification of COVID-19 (n=7-8) or healthy donor (n=7) neutrophils stimulated with auto-or 790 heterologous plasma

Analysis of LDH and DNA (E) as well as DAMPs (F) and cytokines (G) in supernatants of 792

) neutrophils stimulated with auto-or heterologous 793 plasma for 4 h. (H and I) Representative histogram and quantification of GMFI of intracellular 794 RIPK1 expression and caspase-8 activity (I) of COVID-19 (n=9) or healthy donor

Each square or connected 796 squares represent one donor. Shown are mean ± SEM. Statistics were calculated by paired t-797 test or Wilcoxon signed-rank test. P values are indicated within the graphs. (J and K) RIPK1, 798 RIPK3 and MLKL staining of COVID-19 (n = 2) and non-COVID-19 thrombi

Arrows indicate strong 800 positive staining, arrowheads indicate negative or weak positive staining